338 related articles for article (PubMed ID: 7127293)
1. Kinetics of N-(phosphonacetyl)-L-aspartate and pyrazofurin depletion of pyrimidine ribonucleotide and deoxyribonucleotide pools and their relationship to nucleic acid synthesis in intact and permeabilized cells.
Moyer JD; Smith PA; Levy EJ; Handschumacher RE
Cancer Res; 1982 Nov; 42(11):4525-31. PubMed ID: 7127293
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate.
Moyer JD; Handschumacher RE
Cancer Res; 1979 Aug; 39(8):3089-94. PubMed ID: 455293
[No Abstract] [Full Text] [Related]
3. Effect of N-(phosphonacetyl)-L-aspartate on 5-azacytidine metabolism in P388 and L1210 cells.
Grant S; Rauscher F; Jakubowski A; Cadman E
Cancer Res; 1981 Feb; 41(2):410-8. PubMed ID: 6160908
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of cytidine dialdehyde and its effects on nucleotide and nucleic acid synthesis.
Kinahan JJ; Pavelic ZP; Leonard RJ; Bloch A; Grindey GB
Cancer Res; 1980 Mar; 40(3):598-603. PubMed ID: 7471080
[TBL] [Abstract][Full Text] [Related]
5. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
Monks A; Anderson LW; Strong J; Cysyk RL
J Biol Chem; 1983 Nov; 258(22):13564-9. PubMed ID: 6417130
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effects with inhibitors of de novo pyrimidine synthesis, acivicin, and N-(phosphonacetyl)-L-aspartic acid.
Loh E; Kufe DW
Cancer Res; 1981 Sep; 41(9 Pt 1):3419-23. PubMed ID: 7260907
[TBL] [Abstract][Full Text] [Related]
7. Salvage of circulating pyrimidine nucleosides in the rat.
Moyer JD; Oliver JT; Handschumacher RE
Cancer Res; 1981 Aug; 41(8):3010-7. PubMed ID: 7248957
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.
Chan TC; Howell SB
Cancer Res; 1985 Aug; 45(8):3598-604. PubMed ID: 4016741
[TBL] [Abstract][Full Text] [Related]
9. Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
Moore EC; Friedman J; Valdivieso M; Plunkett W; Marti JR; Russ J; Loo TL
Biochem Pharmacol; 1982 Oct; 31(20):3317-21. PubMed ID: 7150358
[TBL] [Abstract][Full Text] [Related]
10. The mechanism of action of 3-deazauridine in tumor cells sensitive and resistant to arabinosylcytosine.
Brockman RW; Shaddix SC; Williams M; Nelson JA; Rose LM; Schabel FM
Ann N Y Acad Sci; 1975 Aug; 255():501-21. PubMed ID: 171997
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of ribonucleoside and deoxyribonucleoside triphosphate pools in cultured leukemia cells during exposure to methotrexate or methotrexate plus thymidine.
Kinahan JJ; Otten M; Grindey GB
Cancer Res; 1979 Sep; 39(9):3531-9. PubMed ID: 476679
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of vaccinia virus replication by N-(phosphonoacetyl)-L-aspartate: differential effects on viral gene expression result from a reduced pyrimidine nucleotide pool.
Katsafanas GC; Grem JL; Blough HA; Moss B
Virology; 1997 Sep; 236(1):177-87. PubMed ID: 9299630
[TBL] [Abstract][Full Text] [Related]
14. Unexpected synergy between N-phosphonacetyl-L-aspartate and cytidine against human tumor cells.
Chan TC; Howell SB
Eur J Cancer Clin Oncol; 1989 Apr; 25(4):721-7. PubMed ID: 2714348
[TBL] [Abstract][Full Text] [Related]
15. Effect of inhibitors of the de novo pyrimidine biosynthetic pathway on serum uridine levels in mice.
Karle JM; Anderson LW; Dietrick DD; Cysyk RL
Cancer Res; 1981 Dec; 41(12 Pt 1):4952-5. PubMed ID: 6171344
[TBL] [Abstract][Full Text] [Related]
16. PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells.
Yang JL; Fernandes DJ; Wheeler KT; Capizzi RL
Int J Radiat Oncol Biol Phys; 1996 Mar; 34(5):1073-9. PubMed ID: 8600090
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2'-deoxyuridine +/- N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26.
van Laar JA; Durrani FA; Rustum YM
Cancer Res; 1993 Apr; 53(7):1560-4. PubMed ID: 8453623
[TBL] [Abstract][Full Text] [Related]
18. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
Ardalan B; Jayaram HN; Johnson RK
Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
[TBL] [Abstract][Full Text] [Related]
19. Differential effect of N-(phosphonacetyl)-L-aspartate on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity in human leukemia and normal bone marrow progenitors.
Grant S; Rauscher F; Cadman E
Cancer Res; 1982 Oct; 42(10):4007-13. PubMed ID: 6955007
[TBL] [Abstract][Full Text] [Related]
20. N-(phosphonacetyl)-L-aspartate synergistically enhances the cytotoxicity of 5-fluorouracil/interferon-alpha-2a against human colon cancer cell lines.
Wadler S; Mao X; Bajaj R; Hallam S; Schwartz EL
Mol Pharmacol; 1993 Nov; 44(5):1070-6. PubMed ID: 8246910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]